Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.

Détails

Ressource 1Télécharger: 37816492.pdf (1104.21 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_575061651828
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Long-term quantitative hepatitis B surface antigen (HBsAg) trajectories in persons with and without HBsAg loss on tenofovir-containing antiretroviral therapy.
Périodique
HIV medicine
Auteur⸱e⸱s
Begré L., Boyd A., Salazar-Vizcaya L., Suter-Riniker F., Béguelin C., Rockstroh J.K., Günthard H.F., Calmy A., Cavassini M., Stöckle M., Schmid P., Bernasconi E., Levrero M., Zoulim F., Wandeler G., Rauch A.
Collaborateur⸱rice⸱s
Swiss HIV Cohort Study (SHCS)
ISSN
1468-1293 (Electronic)
ISSN-L
1464-2662
Statut éditorial
Publié
Date de publication
02/2024
Peer-reviewed
Oui
Volume
25
Numéro
2
Pages
291-298
Langue
anglais
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Improving the understanding of the patterns of quantitative hepatitis B surface antigen (qHBsAg) trajectories associated with HBsAg loss is important in light of novel anti-hepatitis B virus agents being developed. We evaluated long-term qHBsAg trajectories in persons with HIV and HBV during tenofovir-containing antiretroviral therapy in the Swiss HIV Cohort Study.
We included 29 participants with and 29 without HBsAg loss, defined as qHBsAg <0.05 IU/mL. We assessed qHBsAg decline during therapy in both groups and used agglomerative hierarchical clustering to identify different qHBsAg trajectory profiles in persons with HBsAg loss.
The median follow-up time was 11.9 years (IQR 8.4-14.1), and the median time to HBsAg loss was 48 months (IQR 12-96). Among participants with HBsAg loss, 79% had a qHBsAg decline ≥1 log <sub>10</sub> IU/mL 2 years after starting tenofovir. The trajectories in qHBsAg levels during tenofovir therapy were heterogeneous, characterized by five distinct profiles. Among participants without HBsAg loss, only 7% had a qHBsAg decline ≥1 log <sub>10</sub> IU/ml after 2 years.
Most persons with HIV who experienced HBsAg loss had an early decline in qHBsAg levels, with diverse trajectories during long-term tenofovir therapy. In persons without HBsAg loss, qHBsAg levels remained remarkably stable over time.
Mots-clé
Humans, Tenofovir/therapeutic use, Hepatitis B Surface Antigens/therapeutic use, Antiviral Agents/therapeutic use, Cohort Studies, HIV Infections/drug therapy, Hepatitis B, Chronic/drug therapy, Hepatitis B e Antigens/therapeutic use, DNA, Viral, HBsAg, HIV, hepatitis B, tenofovir, trajectories
Pubmed
Web of science
Open Access
Oui
Création de la notice
13/10/2023 13:53
Dernière modification de la notice
13/02/2024 8:30
Données d'usage